| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P N Suresh Kumar, P K Anish, V Rajmoha. Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. Indian journal of psychiatry. vol 58. issue 3. 2019-11-20. PMID:28066010. |
olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. |
2019-11-20 |
2023-08-13 |
Not clear |
| Ileana Berman, Amalia Merson, Julia Rachov-Pavlov, Edward Allan, Michael Davidson, Miklos F Losoncz. Risperidone in Elderly Schizophrenic Patients: An Open-Label Trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 4. issue 2. 2019-11-20. PMID:28531009. |
the authors assessed the safety and efficacy of risperidone in a group of elderly patients with chronic schizophrenia and behavioral disturbances (n = 10). |
2019-11-20 |
2023-08-13 |
Not clear |
| Matthew Morrison, Autumn Schultz, Deborah L Sanchez, Maria C Catalano, Glenn Catalan. Leukopenia Associated with Risperidone Treatment. Current drug safety. 2019-11-20. PMID:28558630. |
risperidone is an atypical antipsychotic agent that was originally approved by the united states food and drug adminstration for the treatment of schizophrenia. |
2019-11-20 |
2023-08-13 |
Not clear |
| b' Eva \\xc4\\x8ce\\xc5\\xa1kov\\xc3\\xa1, Radovan P\\xc5\\x99ikryl, Tom\\xc3\\xa1\\xc5\\xa1 Ka\\xc5\\xa1p\\xc3\\xa1rek, Marta Ondru\\xc5\\xa1ov\\xc3\\xa. Prolactin levels in risperidone treatment of first-episode schizophrenia. International journal of psychiatry in clinical practice. vol 8. issue 1. 2019-11-20. PMID:28621165.' |
prolactin levels in risperidone treatment of first-episode schizophrenia. |
2019-11-20 |
2023-08-13 |
Not clear |
| b' Eva \\xc4\\x8ce\\xc5\\xa1kov\\xc3\\xa1, Radovan P\\xc5\\x99ikryl, Tom\\xc3\\xa1\\xc5\\xa1 Ka\\xc5\\xa1p\\xc3\\xa1rek, Marta Ondru\\xc5\\xa1ov\\xc3\\xa. Prolactin levels in risperidone treatment of first-episode schizophrenia. International journal of psychiatry in clinical practice. vol 8. issue 1. 2019-11-20. PMID:28621165.' |
to evaluate the risperidone effect on prolactin (prl) levels and to analyse the relation between prl change and treatment response in first-episode schizophrenia patients. |
2019-11-20 |
2023-08-13 |
Not clear |
| Pattath Narayanan Suresh Kumar, Seema P Mohemmedali, P K Anish, Chittaranjan Andrad. Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. Indian journal of psychiatry. vol 59. issue 2. 2019-11-20. PMID:28827871. |
cognitive effects with rivastigmine augmentation of risperidone: a 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. |
2019-11-20 |
2023-08-13 |
Not clear |
| Laxmi Naresh Vadlamani, Girish Banwari, Damodharan Dinakaran, Vikas Menon, Chittaranjan Andrad. Olanzapine has poorer efficacy than risperidone for the treatment of the negative symptoms of schizophrenia. Indian journal of psychiatry. vol 59. issue 2. 2019-11-20. PMID:28827880. |
olanzapine has poorer efficacy than risperidone for the treatment of the negative symptoms of schizophrenia. |
2019-11-20 |
2023-08-13 |
Not clear |
| Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwar. A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant. Psychopharmacology bulletin. vol 47. issue 4. 2019-11-20. PMID:28936006. |
a phase-1, 6-month open-label, dose-ranging pharmacokinetic study in stabilized patients with schizophrenia following risperidone implant. |
2019-11-20 |
2023-08-13 |
Not clear |
| Luke Sy-Cherng Woon, Chun Keat Tee, Lydia Lay Yen Gan, Kanit Tha Deang, Lai Fong Cha. Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction? Journal of psychiatric practice. vol 24. issue 2. 2019-11-20. PMID:29509183. |
we report a case of an antipsychotic-naive patient with schizophrenia who developed leukopenia after a single dose of olanzapine, which worsened during subsequent treatment with risperidone. |
2019-11-20 |
2023-08-13 |
Not clear |
| Padraig Wright, Luke O'Flahert. Antipsychotic drugs: atypical advantages and typical disadvantages. Irish journal of psychological medicine. vol 20. issue 1. 2019-11-20. PMID:30440229. |
the atypical antipsychotic drugs currently marketed in ireland for the first line treatment of schizophrenia include amisulpride, olanzapine, quetiapine, risperidone and ziprasidone. |
2019-11-20 |
2023-08-13 |
Not clear |
| Trevor C Chopko, Craig W Lindsle. Classics in Chemical Neuroscience: Risperidone. ACS chemical neuroscience. vol 9. issue 7. 2019-09-30. PMID:29695153. |
risperidone, sold under the trade name risperdal, was the second atypical antipsychotic developed following clozapine but quickly became a first-line treatment for acute and chronic schizophrenia because of its preferential side effect profile. |
2019-09-30 |
2023-08-13 |
Not clear |
| Ana Filipce, Zorica Naumovska, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Katerina Brezovska, Jasmina Tonic-Ribarska, Aleksandra Grozdanova, Ljubica Suturkova, Marija Ralev. Evaluation of Correlation Between the Pharmacogenetic Profiles of Risperidone Treated Psychiatry Patients with Plasma and Urine Concentration of Risperidone and its Active Moiety 9-OH Risperidone Determined with Optimized Bioanalytical LC Method. Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki). vol 39. issue 2-3. 2019-09-26. PMID:30864366. |
atypical antipsychotic risperidone is widely used first-line monotherapy in schizophrenia and combined therapy in bipolar disorders. |
2019-09-26 |
2023-08-13 |
human |
| Charanraj Goud Alladi, Ravi Philip RajKumar, Surendiran Adithan, Cynthia Marie-Claire, Frank Bellivier, Deepak Gopal Shewad. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. Fundamental & clinical pharmacology. vol 33. issue 3. 2019-09-16. PMID:30332506. |
dopamine (drd2) and serotonin (htr2a, 2c) receptor gene polymorphisms do not influence early response to risperidone in south indian patients with schizophrenia. |
2019-09-16 |
2023-08-13 |
Not clear |
| Charanraj Goud Alladi, Ravi Philip RajKumar, Surendiran Adithan, Cynthia Marie-Claire, Frank Bellivier, Deepak Gopal Shewad. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. Fundamental & clinical pharmacology. vol 33. issue 3. 2019-09-16. PMID:30332506. |
to explore further, the present study aimed to assess the influence of drd2 -141 c ins/del, taq1a and htr2a -1438 g/a, 102t/c and htr2c -759 c/t genetic polymorphisms in response to risperidone in patients with schizophrenia. |
2019-09-16 |
2023-08-13 |
Not clear |
| Charanraj Goud Alladi, Ravi Philip RajKumar, Surendiran Adithan, Cynthia Marie-Claire, Frank Bellivier, Deepak Gopal Shewad. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. Fundamental & clinical pharmacology. vol 33. issue 3. 2019-09-16. PMID:30332506. |
the study was conducted among the n = 320 south indian patients with schizophrenia who received risperidone treatment (4-8 mg per day) for a minimum of four weeks. |
2019-09-16 |
2023-08-13 |
Not clear |
| N V Baymeeva, A I Platova, V G Kaleda, I I Miroshnichenk. [Therapeutic drug monitoring of risperidone and its active metabolite 9-hydroxyrisperidone in the treatment of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 119. issue 3. 2019-08-22. PMID:31089091. |
[therapeutic drug monitoring of risperidone and its active metabolite 9-hydroxyrisperidone in the treatment of schizophrenia]. |
2019-08-22 |
2023-08-13 |
Not clear |
| Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwar. Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia. Clinical pharmacology in drug development. vol 7. issue 3. 2019-06-13. PMID:29420868. |
pharmacokinetics and safety of risperidone subcutaneous implants in stable patients with schizophrenia. |
2019-06-13 |
2023-08-13 |
human |
| Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwar. Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia. Clinical pharmacology in drug development. vol 7. issue 3. 2019-06-13. PMID:29420868. |
a subcutaneous risperidone implant (ri) formulation was developed to improve medication adherence in schizophrenia. |
2019-06-13 |
2023-08-13 |
human |
| Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwar. Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia. Clinical pharmacology in drug development. vol 7. issue 3. 2019-06-13. PMID:29420868. |
ri may represent an alternative formulation for schizophrenia treatment with a lower peak-to-trough plasma drug ratio than oral risperidone. |
2019-06-13 |
2023-08-13 |
human |
| Lei Zheng, Lixia Yang, Xin Zhao, Niya Long, Peifan Li, Yiming Wan. Effect of risperidone on proliferation and apoptosis of MC3T3-E1 cells. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. vol 52. issue 3. 2019-06-05. PMID:30810624. |
this aim of this study was to assess the molecular mechanism of osteoporosis in schizophrenia patients with risperidone use. |
2019-06-05 |
2023-08-13 |
Not clear |